8-K current report · filed Aug 3, 2026

SUPERNUS PHARMACEUTICALS, INC. (SUPN) 8-K Current Report: August 3, 2026

Item 8.01Item EX-99.2Item EX-99.3Item EX-99.1SUPN overview

Short answer

SUPERNUS PHARMACEUTICALS, INC. (SUPN) filed an 8-K current report with the SEC on August 3, 2026 reporting Item 8.01 (Other Events), Item EX-99.2 (Exhibit EX-99.2), Item EX-99.3 (Exhibit EX-99.3), Item EX-99.1 (Item EX-99.1). Supernus publicly promoted its proposed merger of equals with Indivior on August 3, 2026.

SUPERNUS PHARMACEUTICALS, INC. 8-K event analysis

AI summary of each reported item and its exhibits

Item 8.01 · Other Events

  • Supernus publicly promoted its proposed merger of equals with Indivior on August 3, 2026
  • Employee communications indicate active merger preparation, but do not establish transaction completion
  • Investors should monitor the forthcoming Form S-4 and joint proxy statement for exchange ratio, approvals, and closing conditions
  • Fixed exchange ratio exposes shareholders to market-price risk before closing
  • Additional debt financing for a Special Dividend could increase combined-company leverage after closing

Item EX-99.1 · Item EX-99.1

  • All-stock merger of equals with Indivior creates a broader CNS and behavioral-health platform
  • Combined portfolio includes SUBLOCADE, Qelbree, Zurzuvae, Onapgo, and GOCOVRI
  • Closing targeted for Q4 2026, subject to shareholder, regulatory, and other approvals
  • Jack will become CEO, with Supernus leadership joining the expanded management team
  • Fixed exchange ratio and potential financing for a Special Dividend create shareholder and leverage risks

Item EX-99.2 · Exhibit EX-99.2

  • All-stock merger of equals with Indivior, creating a broader U.S. CNS biopharma platform
  • Four commercial franchises: SUBLOCADE, Qelbree, Zurzuvae, and Onapgo/GOCOVRI
  • Closing targeted for Q4 2026, pending stockholder and regulatory approvals
  • Supernus leadership joins the expanded organization, with Indivior’s CEO becoming combined-company CEO
  • Financing for a Special Dividend and additional merger-related indebtedness introduce balance-sheet execution risk

Item EX-99.3 · Exhibit EX-99.3

  • Proposed merger of equals with Indivior, subject to HSR filing, deal signing and shareholder and regulatory approvals
  • Combined portfolio generated $2.162 billion LTM net revenue through 6/30/26 across 11 commercial products
  • Strategic rationale: diversified CNS leader spanning addiction, psychiatry and neurology, with SUBLOCADE and Qelbree key growth franchises
  • Closing targeted for Q4 2026, creating execution, integration and approval risks before benefits materialize
  • Current Supernus employees expected to remain in existing roles, with leadership joining the combined company നേതൃത്വം

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other SUPERNUS PHARMACEUTICALS, INC. 8-K filings

Get the next SUPN 8-K as it lands

Follow SUPN for push alerts, or ask the research agent what this filing means.